Moderna Aktie News

Over the past couple of years, Moderna (MRNA 3.39%) and Regeneron Pharmaceuticals (REGN -0.62%) have encountered company-specific headwinds that have sunk their stock prices. The former is down by 75% over this period, while the latter has dropped 32%.

Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited for consistent covered call trades. Covered call strategies offer downside protection in the underperforming, high-beta biotech sector, supporting a rinse, wash, and repeat approach.

President Donald Trump delivered the pharmaceutical industry another blow this week, threatening 100% tariffs on some companies.

Moderna, Inc. (NASDAQ:MRNA ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 25, 2025 10:30 AM EDT Company Participants Rose Loughlin - Executive Vice President of Research Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.

The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population The facility marks a cornerstone of Moderna's ten-year strategic partnership with the UK Government, designed to strengthen health resilience and drive economic growth CAMBRIDGE, MA / ACCESS Newswire / September 24, 2...

Moderna (MRNA) remains a Sell due to weak fundamentals, ongoing cash burn, and lack of meaningful pipeline breakthroughs or financial turnaround. MRNY, the YieldMax MRNA Option Income Strategy ETF, fails to deliver significant drawdown protection or outperformance in flat or correcting markets. MRNY's high headline yield is misleading, as structural NAV erosion and high expenses erode real retu...

Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and older, as well as in individuals aged 12 to 64 with at least one underlying risk condition.

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains CAMBRIDGE, MA / ACCESS Newswire / September 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today...